Canadian Cancer Trials Group Bulletins


Trial Activations

IND.186 -- Phase II portion -- Study of Sorafenib ENIB (BAY 43-9006) in Combination with Low Dose ARA-C (Cytarabine) in Elderly Patients with AML or High-Risk MDS -- was centrally activated 7 January 2009.

CL.3 -- A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia -- was centrally activated 13 January 2009.